Malignant Tumors of the Larynx Guidelines

Updated: Apr 13, 2021
  • Author: Jonas T Johnson, MD, FACS; Chief Editor: Arlen D Meyers, MD, MBA  more...
  • Print

Guidelines Summary

Head and neck cancer guidelines published in November 2017 by the Spanish Society of Medical Oncology included the following options for laryngeal cancer [16, 17] :

  • Surgical resection (total versus partial laryngectomy + neck dissection) followed by radiotherapy or chemoradiotherapy if pathologic factors have a high recurrence risk, particularly T4a; for the most part of subglottic tumors
  • If the patient refuses surgery, then concurrent chemoradiotherapy with thrice-weekly cisplatin; the use of cetuximab concurrent to radiotherapy is recommended if cisplatin cannot be administered
  • Induction chemotherapy with TPF (docetaxel/cisplatin/fluorouracil) schedule (except for subglottic tumors)

With the induction chemotherapy option, the guidelines recommend the following [16, 17] :

  • If complete response - Radiotherapy
  • If partial response - Concomitant radiotherapy (with cisplatin or cetuximab), or consider surgery followed by radiotherapy
  • If stable disease or progression - Surgery (including neck dissection) followed by radiotherapy or chemoradiotherapy